Lee Financial’s Arbutus Biopharma ABUS Stock Holding History

Lee Financial’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-50	Closed	–	–	466
2017 Q3	$0	Hold	50	–	–	﹤0.01%	474
2017 Q2	$0	Hold	50	–	–	﹤0.01%	497
2017 Q1	$0	Hold	50	–	–	﹤0.01%	401
2016 Q4	$0	Buy	+50	New	+$145	﹤0.01%	416

Other funds holding ABUS

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lee Financial's ABUS Position: Q4 2017 in Review

Lee Financial sold out of Arbutus Biopharma (ABUS) in Q4 2017, closing a stake of 50 shares.

Lee Financial first reported a position in ABUS in Q4 2016 and held it in 4 quarters. The position peaked at $0 in Q3 2017. 51 funds tracked by Wall St. Rank hold ABUS as of Q4 2017.

Lee Financial reported no remaining Arbutus Biopharma position as of Q4 2017 after selling out during the quarter.
Lee Financial sold 50 Arbutus Biopharma shares in Q4 2017.
Lee Financial first reported a position in Arbutus Biopharma in Q4 2016 and held it in 4 quarters.
Lee Financial's Arbutus Biopharma position peaked at $0 in Q3 2017.
51 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2017.

Based on Lee Financial's 13F filing for Q4 2017, filed 9 Feb 2018.